# Immunomodulation With Eltrombopag in ITP

> **NCT04812483** · PHASE2 · COMPLETED · sponsor: **University Children's Hospital Basel** · enrollment: 2 (actual)

## Conditions studied

- Primary Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** Eltrombopag (Revolade®)
- **DRUG:** standard therapy (without eltrombopag): HD-DXM

## Key facts

- **NCT ID:** NCT04812483
- **Lead sponsor:** University Children's Hospital Basel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-01
- **Primary completion:** 2024-04-11
- **Final completion:** 2024-04-11
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04812483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04812483, "Immunomodulation With Eltrombopag in ITP". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04812483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*